Close Menu

NEW YORK – The US Food and Drug Administration on Friday approved Bristol Myers Squibb and Bluebird Bio's CAR T-cell therapy, idecabtagene vicleucel (Abecma), for patients with relapsed or refractory multiple myeloma who have previously received at least four lines of treatment, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.